Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


3 Reasons to Avoid BAX and 1 Stock to Buy Instead

2026-03-27
What a brutal six months it’s been for Baxter. The stock has dropped 24.9% and now trades at $16.81, rattling many shareholders. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

Clinical Nutrition for Cancer Care: 2026-2030 Market Analysis Featuring Profiles of Leading Players - Abbott Nutrition, Baxter International, B Braun Melsungen, Nestle Health Science, Danone Nutricia and More

2026-03-27
Clinical Nutrition for Cancer Care Market Clinical Nutrition for Cancer Care Market Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Clinical Nutrition for Cancer Care Market Report 2026" has been added to ResearchAndMarkets.com's offering. The clinical nutrition for cancer care market has experienced substantial growth, with the market size set to increase from $5.16 billion in 2025 to $5.42 billion in 2026, representing a compound annual growth rate (CAGR) of 5.1%. This upward trend is driven b

Bank of America Maintains a Hold Rating on Baxter International (BAX)

2026-03-27
Baxter International Inc. (NYSE:BAX) is one of the Best Mid Cap Value Stocks to Buy in 2026. On March 17, Travis Steed from Bank of America Securities maintained a Hold rating on Baxter International Inc. (NYSE:BAX) with a price target of $24. ​The rating comes after the S&P downgraded its outlook on the stock from […]

Baxter to Host Annual Meeting of Stockholders in Virtual Format

2026-03-25
DEERFIELD, Ill., March 25, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, con

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

2026-03-25
Pet Partners, the nation's leading organization dedicated to improving human health and well-being through therapy animal interactions, and the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced a new partnership to expand access to therapy animal programs in healthcare settings across the country. The initiative will begin as a two-year pilot program in key regions, including Northern California, Upstate New York and Greate

EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks

2026-03-25
Oil prices have risen. Here's how Strait of Hormuz tensions could soon increase healthcare costs and make everyday medical supplies more expensive.

U.S Stocks Futures Pullback as Middle East Jitters Trump Peace Hopes

2026-03-24
Futures down on Iran Military Action

Manufacturing Disruption Hits Baxter Cancer Drug Supply In Europe

2026-03-24
Baxter warns of an EU-wide ifosfamide shortage until next year after manufacturing disruption, with supply quotas and treatment prioritization in place.

Baxter Notifying Healthcare Professionals About Ifosfamide-Containing Medicinal Products Shortage

2026-03-24
https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-holoxan-tronoxal-mitoxana-ifosfamide-500-mg-1-g-2-g-powder-solution-injection_en.pdf

How Is Baxter's Stock Performance Compared to Other Medical Devices Stocks?

2026-03-18
Baxter has notably underperformed the Medical Devices industry over the past year, and analysts are cautious about the stock’s prospects.